Investigational Site Number :0360003

Wollongong, New South Wales 2500

1 studies enrolling now · 3 studies all time

What they study most

Plasma Cell Myeloma, Plasma Cell Myeloma Recurrent

Studies at this site

• International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab — Enrolling by invitation
• SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM — Running, not enrolling
• Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients — Completed